In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the management of small cell lung cancer using a virtual tumor board format. SCLC is an aggressive subtype of lung cancer, and for patients with advanced or extensive-stage disease, the current first-line standard of care is chemo-immunotherapy. For those who do not achieve long-term disease control, second-line options are somewhat limited. Dr. Liu, Dr. Blackhall, and Dr. Shields discuss currently available treatment options (platinum-retreatment, lurbinectedin, topotecan) and some promising drugs in development for SCLC.